OBJECTIVES: The aims of this review were 1) to estimate the disutility of patients suffering from psoriasis vulgaris, using the mean EQ5D index scores and 2) to compare this to patients suffering from cancer (prostate, breast, Hodgkin/non-Hodgkin lymphoma, the digestive system) and cardiovascular diseases (angina and heart failure). METHODS: A systematic literature search was conducted in December 2013 in EMBASE, MEDLINE and CENTRAL using search terms EQ5D OR EQ OR EUROQoL AND Psoriasis AND/OR Vulgaris. The following inclusion criteria were used: original research, full length papers available, mild, moderate and severe psoriasis vulgaris, EQ5D, English written. Four independent reviewers reviewed the titles, abstracts and full length papers. The full length papers meeting the inclusion criteria were analyzed in a data extraction table. A separate search was conducted to identify already published systematic literature reviews in psoriasis or any other disease reporting on utility based on EQ5D. The results were qualitatively compared to those reviews. RESULTS: In the first search, 133 titles were identified, however after 3 rounds of reviews (excluding 65 Titles, 44 Abstracts, 7 Full length papers) 17 papers were found to meet the inclusion criteria. For patients suffering from psoriasis vulgaris the mean EQ5D-index scores ranged from 0.52 (standard deviation 0.39) to 0.90 (standard deviation 0.10) for all disease severities. The second search identified two systematic literature reviews one in cancer and one in cardiovascular diseases investigating utility based on EQ5D. Corresponding ranges for cancer and cardiovascular diseases are 0.33 (standard deviation 0.4) to 0.93 (standard deviation 0.12) and 0.24 (standard deviation 0.39) to 0.90 (standard deviation 0.16) respectively. CONCLUSIONS: The ranges of disutility in quality of life among patients suffering from psoriasis vulgaris identified in this review are within the same range as for patients suffering from cancer or cardiovascular diseases.